Comparison of short-term treatment regimen of ciprofloxacin versus long-term treatment regimens of trimethoprim/sulfamethoxazole or norfloxacin for uncomplicated lower urinary tract infections: a randomized, multicentre, open-label, prospective study | Zendy

José Luis Arredondo-Garcı́a | Zendy; Ricardo Figueroa-Damián | Zendy; Alejandro Rosas | Zendy; Arturo Jáuregui | Zendy; Mauricio Corral | Zendy; Alexis Costa | Zendy; Roberto Mauricio Merlos | Zendy; Antonio Ríos-Fabra | Zendy; Carlos F. Amábile-Cuevas | Zendy; Gerardo Hernández-Oliva | Zendy; Jorge Olguín | Zendy; Oscar Cardeñosa-Guerra | Zendy

Open Access

Comparison of short-term treatment regimen of ciprofloxacin versus long-term treatment regimens of trimethoprim/sulfamethoxazole or norfloxacin for uncomplicated lower urinary tract infections: a randomized, multicentre, open-label, prospective study

Author(s) -

José Luis Arredondo-Garcı́a,

Ricardo Figueroa-Damián,

Alejandro Rosas,

Arturo Jáuregui,

Mauricio Corral,

Alexis Costa,

Roberto Mauricio Merlos,

Antonio Ríos-Fabra,

Carlos F. Amábile-Cuevas,

Gerardo Hernández-Oliva,

Jorge Olguín,

Oscar Cardeñosa-Guerra

Publication year - 2004

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkh414

Subject(s) - medicine , norfloxacin , regimen , trimethoprim , sulfamethoxazole , ciprofloxacin , open label , urinary system , antibacterial agent , randomized controlled trial , antibiotics , surgery , microbiology and biotechnology , biology

To compare the bacteriological and clinical efficacy of three treatments for uncomplicated cystitis in ambulatory pre-menopausal women: ciprofloxacin 250 mg orally twice daily for 3 days, trimethoprim/sulfamethoxazole 160/800 mg orally twice daily for 7 days, and norfloxacin 400 mg orally twice daily for 7 days.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research